Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2017-03-09 Capital/Financing Update
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2017, by TG Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of common stock. The document details the terms of the offering, the number of shares, pricing, underwriting discounts, and related expenses. It also includes exhibits such as the underwriting agreement and legal opinion. The content focuses on a financing transaction and capital raising activity. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory certification or voting result announcement. The primary subject is the update on the company's capital raising through a public offering, which fits the Capital/Financing Update category.
2017-03-09 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a common stock offering by TG Therapeutics, Inc. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule related to prospectus supplements for securities offerings. The content focuses on the terms and conditions of a stock offering, underwriting details, and related disclosures. This type of document is a capital/financing update as it pertains to the company's fundraising activities through issuing common stock. It is not an annual report, earnings release, or any other type of report but specifically a financing-related filing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2017-03-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the issuance of a press release reporting topline results from a Phase 3 clinical trial. There are no detailed financial statements or comprehensive financial data included, only a reference to the press release as an exhibit. The document length is short (2271 characters), and it primarily serves as an announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-03-06 English
SC 13G/A
Major Shareholding Notification
2017-02-15 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.